Clinical Efficacy of Modified Qingqi Huatan Wan in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Effect on Inflammatory Reaction, Airway Remodeling and Thrombokinesis
10.13422/j.cnki.syfjx.20182427
- VernacularTitle: 清气化痰丸加减治疗慢性阻塞性肺疾病急性加重期的临床疗效及对患者炎性反应、气道重塑和血栓形成机制的影响
- Author:
Ti-bao HOU
1
;
Rui LIU
1
;
Jia HE
1
;
Chuan-dong YE
1
Author Information
1. Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China
- Publication Type:Research Article
- Keywords:
acute exacerbation of chronic obstructive pulmonary disease;
airway remodeling;
thrombokinesis;
matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 (MMP-2/TIMP-2);
plasma tissue-plasminogen activator/plasminogen activator inhibitor-1 (t-PA/PAI-1);
modified Qingqi Huatan Wan
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(10):74-80
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical efficacy of Modified Qingqi Huatan Wan in treatment of acute exacerbation of chronic obstructive pulmonary disease and its effect on inflammatory reaction, airway remodeling and thrombokinesis. Method:A total of 80 patients of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) were randomly divided into control group (40 cases) and therapy group (40 cases) by random number table. The control group was treated with conventional therapy. In addition to the therapy for the control group, the patients in therapy group also received modified Qingqi Huatan Wan. The treatment course was 14 days for both groups. Scores of traditional Chinese medicine(TCM) syndrome, chronic obstructive pulmonary disease and asthma physiology Score (CAPS), and chronic obstructive pulmonary disease patients self-assessment test questionnaire (CAT) were compared. The secondary indicators were pulmonary function, arterial blood gas analysis, and blood rheology indexes. In addition, the levels of serum nuclear factor kappa B (NF-κB), interleukin-6 (IL-6), interleukin-8 (IL-8), matrix metalloproteinase-2 (MMP-2), tissue inhibitor of metalloproteinase-2 (TIMP-2), transforming growth factor-beta1 (TGF-β1) and plasma tissue-plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), von-willebrand factor (v-WF), clinical efficacy and safety were evaluated. Result:The total clinical effective rate was 94.74% in therapy group,which was higher than 78.38% in control group (χ2=4.341,P<0.05). After treatment, scores of TCM syndrome, CAPS, CAT and levels of PaCO2, serum NF-κB, IL-6, IL-8, MMP-2, TIMP-2, TGF-β1 and plasma PAI-1, v-WF in therapy group were lower than those in control group(P<0.05). However, levels of plasma t-PA, SaO2, PaO2, FEV1, FEV1%, FEV1/FVC in therapy group were higher than those in control group(P<0.05), therapy group was alleviated more than control group (P<0.05). Conclusion:Modified Qingqi Huatan Wan can control the symptoms safely, alleviate CAPS and lung function, effectively reduce the inflammatory response and inhibit the formation of airway remodeling and thrombosis, and its mechanism may be protect the lung tissue by reducing the level of inflammatory cytokines, regulating the balance of MMP-2/TIMP-2 and t-PA/PAI-1 and improving extracellular matrix and vascular endothelial function.
